Injectable pharmaceutical suspension comprising posaconazole

Abstract

The present invention provides formulations useful for treating infections, in particular, formulations that include the active pharmaceutical ingredient posaconazole in an injectable suspension that is stable when subjected to terminal steam sterilization.

Description

field of invention [0001] The present invention relates to formulations for the treatment of infections. In particular, these formulations include injectable suspensions of the active pharmaceutical ingredient posaconazole which are stable upon terminal steam sterilization and throughout the shelf life of the product. Background of the invention [0002] Posaconazole is an antifungal drug represented by the following chemical structure: [0003] [0004] It has been developed as an oral suspension (40 mg / ml) by Schering Corporation, Kenilworth, NJ. under the trade name NOXAFIL(R), see for example US Patent Nos. 5,703,079, 5,661,151, WO 02 / 80678 published October 17, 2002 and EP 1 372 394 published January 2, 2004. Additionally, other formulations of posaconazole have been disclosed. Solid formulations (capsules / tablets) of posaconazole are disclosed in US Patent Nos. 5,972,381 and 5,834,472. Finally, topical forms of posaconazole such as lotions, creams, ointments or ...

AI Technical Summary

Problems solved by technology

[0006] However, none of the above references discloses a posaconazole injectable suspension that remains stable through terminal steam sterilization and throughout the shelf life of the product.

Images